Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team
Eksterne analyser

Aspo: Several transactions have reshaped the company - Nordea

Aspo

Dette er en ekstern analyse og afspejler ikke nødvendigvis vores perspektiv eller værdier.

Download analyse (PDF)
Aspo sold its Leipurin segment at a relatively good price in Q3 2025. The Telko segment could still suffer from the weak market environment, we argue, but ESL Shipping improved in Q3 compared to H1 2025. Overall industrial activity is not very strong, which could put some pressure on reaching the midpoint of its full-year EBITA guidance of EUR 40m in 2025, yet this guidance of EUR 35-45m includes the Leipurin segment. The same guidance range without Leipurin could be EUR 29-39m, we calculate. We now exclude the Leipurin segment from reported figures on a pro forma basis for 2025E to follow the new reporting structure, which is also the main reason for our estimate revisions. Our long-term growth and margin assumptions point to a new fair value range of EUR 6.7-8.2 (6.3-7.7), based on an equal weighting of our DCF, P/E and SOTP valuations.
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.